Breast The Journal of the National Cancer Institute just published the results of a large study evaluating the survival benefit of contralateral prophylactic mastectomy in the surgical treatment of breast cancer. In some mastectomy patients, breast cancer will reoccur in the remaining breast, and that risk can be reduced (but not eliminated) by removing the non-cancerous breast .

Contralateral prophylactic mastectomy lowers post-mastectomy five-year death rate by 30%

The five-year death rate after mastectomy was 11.5% for women who had both breasts removed. It was 16.3% for those who only had the cancerous breast removed. Adding a contralateral prophylactic mastectomy to the original surgery therefore reduced the five-year death rate from 16.3% to 11.5%. Almost a third fewer mastectomy patients died within 5 years when the had chosen to remove the second (healthy) breast, compared to mastectomy patients who had not chosen to remove the second breast. The bilateral mastectomy decreased the 5-year death rate by 29.4%.

This strikes me as a significant benefit. Suppose I have breast cancer and need a mastectomy. I can choose a single mastectomy and have a one-in-6 chance of dying in five years, or I can choose a double mastectomy and have a one-in-9 chance of dying in five years. One-in-9 sounds quite a bit better to me. If 100,000 women with unilateral cancer need mastectomies, performing 100,000 double mastectomies instead of 100,000 unilateral mastectomies will reduce the number of deaths in the first five years from 16,300 to 11,500. About 4,800 fewer women will die within five years.

Contralateral prophylactic mastectomy benefits only 5% of mastectomy patients.

The reporting of this study takes a very different viewpoint. It compares the survival rate, not the death rate, and notes that the bilateral prophylactic mastectomy increases the survival rate from 83.7% to 88.5%, “a difference of less than 5%.” Five percent sounds like a small number, but 5,000 lives saved sounds like a large number.

Point of view

Both statements (lowers by 30%; benefits only 5%) are the same. Only the intent to communicate is different. Whether prophylactic mastectomy is good practice depends not only on the change in five-year survival rate, and I don’t have more information.. For example, how does a double mastectomy (which for 95,000 of the women will not change the five-year death rate outcome) affect a woman’s well-being and general health over time? What is the cost to save these 5,000 lives, and how will the disparity of death rates change more than five years after surgery?

 

Good news

There is a good piece of news in the study: The study data identified a subgroup of women for whom double mastectomy had an even greater benefit: women 50 and younger with early stage estrogen receptor negative cancer. Removing the second breast had no benefit for women 60 and older, and the benefit for women in their 50s was uncertain, presumably because of the small number of bilateral mastectomies in the sample.

The journalists writing about this study generally downplayed the benefits. It would have been better for them to downplay the benefits on most of the women, but hype the discovery that there is a subgroup of women who might get a substantial benefit from this procedure. If you read the study, or find better summaries of it, you may find that this study can help patients and doctors make wise treatment choices (contralateral mastectomy sometimes among them). With luck and more studies like this, prophylactic mastectomies might in the future go only to those women whom they might help. With even more luck, we’ll improve our diagnosis and prevention of breast cancer and the number of mastectomies will go down.